The aim of the study was the assessment of antipsychotic treatment discontinuation risk during 12 months observation period and comparison of biochemical parameters changes of metabolic syndrome in Polish patients included in EUFEST.
94 patients with I episode of schizophrenia, schizophreniform and schizoaffective disorders (acc. DSM - IV), previously untreated with antipsychotics were enrolled in the study. They were randomized to receive haloperidol in low doses and SGAs in therapeutic doses: olanzapine, quetiapine, amisulpride. The following laboratory and antropometric parameters were assessed: glucose level, HDL and LDL cholesterol and TG, weight and height, waist circumstance, and BMI was calculated before the start and after one year of the study. Any cause discontinuation risk of different antipsychotics and differences in mean changes of biochemical parameters during the study were analyzed.
In the polish group of patients enrolled in EUFEST any–cause discontinuation risk of low dose haloperidol was signifi - cantly higher than SGAs. The risk of any cause discontinuation of individual SGAs was not signifi cantly different, although the risk of quetiapine discontinuation was the lowest. No statistical differences in the mean changes of biochemical parameters of metabolic syndrome were observed between patients treated with individual antipsychotics during the study, but quetiapine and amisulpride caused higher, but no signifi cant increase of lipids than olanzapine and haloperidol, and olanzapine caused higher, but no siginifi cant, increase of fasting glucose level than remaining antipsychotics.